User profiles for "author:S Girish"

Sandhya Girish

- Verified email at gilead.com - Cited by 5741

Shabari Girish

- Verified email at rptu.de - Cited by 107

Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2–positive cancer

PM LoRusso, D Weiss, E Guardino, S Girish… - Clinical Cancer …, 2011 - AACR
Abstract Trastuzumab emtansine (T-DM1) is a human epidermal growth factor receptor
(HER2)–targeted antibody-drug conjugate, composed of trastuzumab, a stable thioether …

[HTML][HTML] Personalized cancer vaccines: clinical landscape, challenges, and opportunities

…, I Hosseini, BQ Shen, A Rotte, P Twomey, S Girish… - Molecular Therapy, 2021 - cell.com
Tremendous innovation is underway among a rapidly expanding repertoire of promising
personalized immune-based treatments. Therapeutic cancer vaccines (TCVs) are attractive …

[HTML][HTML] Bioactive compounds in oxidative stress-mediated diseases: Targeting the NRF2/ARE signaling pathway and epigenetic regulation

…, R Samynathan, M Ali Shariati, M Rebezov, S Girish… - Antioxidants, 2021 - mdpi.com
Oxidative stress is a pathological condition occurring due to an imbalance between the
oxidants and antioxidant defense systems in the body. Nuclear factor E2-related factor 2 …

[HTML][HTML] Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)–positive breast cancer …

…, IE Krop, RA Michaelson, S Girish… - Journal of Clinical …, 2011 - scholarship.miami.edu
Purpose The antibody-drug conjugate trastuzumab-DM1 (T-DM1) combines the biologic
activity of trastuzumab with targeted delivery of a potent antimicrotubule agent, DM1, to …

[PDF][PDF] Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer

…, S Modi, SF Jones, SN Holden, W Yu, S Girish… - J Clin Oncol, 2010 - academia.edu
Purpose Trastuzumab-DM1 (T-DM1) is an antibody-drug conjugate that uses trastuzumab to
specifically deliver the maytansinoid antimicrotubule agent DM1 to HER2-positive cells. This …

A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer who were previously treated …

…, E Guardino, M Lu, M Zheng, S Girish… - Journal of clinical …, 2012 - ascopubs.org
Purpose To determine whether the antibody-drug conjugate trastuzumab emtansine (T-
DM1), which combines human epidermal growth factor receptor 2 (HER2)–targeted delivery …

[HTML][HTML] Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer

S Girish, M Gupta, B Wang, D Lu, IE Krop… - Cancer chemotherapy …, 2012 - Springer
Abstract Purpose Trastuzumab emtansine (T-DM1) is an antibody–drug conjugate
comprising trastuzumab and DM1, a microtubule polymerization inhibitor, covalently bound …

[PDF][PDF] Clock regulation of metabolites reveals coupling between transcription and metabolism

…, LJ Francey, S Mukherjee, S Girish… - Cell metabolism, 2017 - cell.com
The intricate connection between the circadian clock and metabolism remains poorly
understood. We used high temporal resolution metabolite profiling to explore clock …

[HTML][HTML] Preclinical safety profile of trastuzumab emtansine (T-DM1): mechanism of action of its cytotoxic component retained with improved tolerability

…, J Tibbitts, S Kaur, O Saad, JH Yi, S Girish… - Toxicology and applied …, 2013 - Elsevier
Abstract Trastuzumab emtansine (T-DM1) is the first antibody-drug conjugate (ADC)
approved for patients with human epidermal growth factor receptor 2 (HER2)-positive …

Potential mechanisms for thrombocytopenia development with trastuzumab emtansine (T-DM1)

…, D Hartley, MX Sliwkowski, S Girish… - Clinical Cancer …, 2015 - AACR
Abstract Purpose: Trastuzumab-emtansine (T-DM1) is an antibody–drug conjugate (ADC)
comprising the cytotoxic agent DM1 conjugated to trastuzumab with a stable linker …